| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.1754C |
| P356 | DOI | 10.1073/PNAS.030545097 |
| P932 | PMC publication ID | 26508 |
| P698 | PubMed publication ID | 10677530 |
| P5875 | ResearchGate publication ID | 24457094 |
| P2093 | author name string | Rehemtulla A | |
| Chenevert TL | |||
| Chinnaiyan AM | |||
| Hamstra DA | |||
| Prasad U | |||
| Ross BD | |||
| Shanaiah M | |||
| Shankar S | |||
| P2860 | cites work | A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain | Q24306835 |
| FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis | Q24307362 | ||
| The receptor for the cytotoxic ligand TRAIL | Q24310481 | ||
| Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death | Q24336389 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| A novel receptor for Apo2L/TRAIL contains a truncated death domain | Q28255451 | ||
| TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling | Q28267294 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex | Q28283294 | ||
| Apoptosis by death factor | Q28304002 | ||
| Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging | Q30606326 | ||
| Apoptosis control by death and decoy receptors | Q33597389 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| An induced proximity model for caspase-8 activation. | Q34065853 | ||
| Two TNF receptors | Q35231014 | ||
| The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity | Q36354661 | ||
| Lethal effect of the anti-Fas antibody in mice | Q36696599 | ||
| Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding | Q36706865 | ||
| The radiobiology of human cells and tissues. In vitro radiosensitivity. The picture has changed in the 1980s | Q38367358 | ||
| Fas and Fas ligand: a death factor and its receptor. | Q40398073 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Early growth response-1-dependent apoptosis is mediated by p53. | Q41094563 | ||
| Sublethal damage, potentially lethal damage, and chromosomal aberrations in mammalian cells exposed to ionizing radiations | Q41169801 | ||
| FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis | Q41224805 | ||
| Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis | Q41433540 | ||
| Down-regulation of bcl-2 by p53 in breast cancer cells. | Q41473714 | ||
| Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). | Q43806672 | ||
| Combined effects of angiostatin and ionizing radiation in antitumour therapy | Q47762838 | ||
| Optimized isotropic diffusion weighting. | Q52335492 | ||
| Removal of endotoxin from recombinant protein preparations. | Q54560669 | ||
| p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha | Q62746018 | ||
| Amplification of c-erbB-2 and aggressive human breast tumors? | Q68144080 | ||
| Removal of endotoxin from protein solutions by phase separation using Triton X-114 | Q68480102 | ||
| Mutant p53-induced immortalization of primary human mammary epithelial cells | Q71170357 | ||
| Fas-mediated apoptosis in primary cultured mouse hepatocytes | Q71660111 | ||
| Mutant p53 proteins behave in a dominant, negative fashion in vivo | Q72525589 | ||
| Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells | Q77319256 | ||
| Treatment of breast cancer | Q77350843 | ||
| Mining the genome for drugs | Q78215566 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| adaptive radiation therapy | Q180507 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 1754-1759 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy | |
| P478 | volume | 97 |
| Q33578562 | 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2 |
| Q31140219 | A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone |
| Q47549547 | A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma |
| Q37418257 | A new dawn for the use of traditional Chinese medicine in cancer therapy. |
| Q34990836 | A transgenic mouse for imaging caspase-dependent apoptosis within the skin |
| Q33522351 | Acute toxicity of a single dose DATR, recombinant soluble human TRAIL mutant, in rodents and crab-eating macaques |
| Q63865750 | Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect |
| Q40488102 | Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer |
| Q34384021 | Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer |
| Q40488966 | Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway |
| Q40354471 | Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model |
| Q39659194 | Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. |
| Q31087174 | Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector |
| Q37425788 | Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells |
| Q40529884 | Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. |
| Q34532325 | Apo2L/TRAIL and its death and decoy receptors |
| Q39874761 | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma |
| Q28176737 | Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy |
| Q39790634 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer |
| Q36850158 | Apoptosis in the development of the immune system |
| Q38309197 | Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage |
| Q57384572 | Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects |
| Q34395580 | Apoptosis regulators and their role in tumorigenesis |
| Q36194579 | Arsenic trioxide: an anti cancer missile with multiple warheads. |
| Q84557313 | BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells |
| Q42199556 | Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells |
| Q40477763 | Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. |
| Q41925102 | Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners |
| Q37133814 | Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody |
| Q43682296 | CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release |
| Q34266298 | CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies |
| Q52583854 | Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. |
| Q39872214 | Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. |
| Q35091128 | Cell surface Death Receptor signaling in normal and cancer cells |
| Q73484476 | Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells |
| Q37066527 | Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. |
| Q24791433 | Chemoresistance in human ovarian cancer: the role of apoptotic regulators |
| Q35094229 | Chemotherapeutic approaches for targeting cell death pathways |
| Q35184335 | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders |
| Q34885147 | Clinical significance of magnetic resonance imaging findings in rectal cancer |
| Q40639389 | Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. |
| Q37832083 | Combined modality therapy with TRAIL or agonistic death receptor antibodies. |
| Q33240972 | Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo |
| Q40516619 | Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells |
| Q37603804 | Current concepts in clinical radiation oncology |
| Q83347429 | DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy |
| Q28217065 | Death and anti-death: tumour resistance to apoptosis |
| Q37116325 | Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. |
| Q34490973 | Death receptors and apoptosis. Deadly signaling and evasive tactics |
| Q35743149 | Death receptors in chemotherapy and cancer |
| Q37660616 | Death receptors: targets for cancer therapy |
| Q36962657 | Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation |
| Q34695283 | Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor |
| Q43630288 | Differential gene expression of human keratinocyte HaCaT cells induced by fibroblast growth factor 10 treatment |
| Q73704158 | Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions |
| Q38601765 | Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. |
| Q30599587 | Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy |
| Q31037179 | Diffusion MRI in early cancer therapeutic response assessment |
| Q33388183 | Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck |
| Q30770455 | Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study |
| Q37170947 | Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. |
| Q43480237 | Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. |
| Q55920968 | Divergent Roles for TRAIL in Lung Diseases |
| Q37360234 | Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer |
| Q39445601 | ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. |
| Q34029449 | Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma |
| Q30682911 | Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy |
| Q37001575 | Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging |
| Q37618351 | Effects of Normothermic Conditioned Microwave Irradiation on Cultured Cells Using an Irradiation System with Semiconductor Oscillator and Thermo-regulatory Applicator |
| Q35100683 | Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus |
| Q39360115 | Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells |
| Q40729349 | Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors |
| Q39983073 | Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. |
| Q37072265 | ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells |
| Q39700468 | Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. |
| Q39747261 | Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers |
| Q36558024 | Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy |
| Q37097913 | Feedback Regulation in a Cancer Stem Cell Model can Cause an Allee Effect. |
| Q52625086 | Ferroptosis-induced Endoplasmic Reticulum Stress: Crosstalk Between Ferroptosis and Apoptosis. |
| Q35698555 | Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival |
| Q30986317 | Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response |
| Q28296081 | GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer |
| Q92281756 | Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences |
| Q35925611 | Gene therapy strategies to improve the effectiveness of cancer radiotherapy |
| Q40054910 | Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells |
| Q46494095 | HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma |
| Q38863729 | Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha |
| Q40153288 | Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells |
| Q38514697 | Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death |
| Q28505264 | Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| Q33739941 | Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening |
| Q27314960 | Imaging proteolytic activity in live cells and animal models |
| Q26863654 | Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts |
| Q40456891 | In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. |
| Q44060524 | In vivo diffusion-weighted MRI of the breast: potential for lesion characterization |
| Q44141786 | Increasing endogenous ceramide using inhibitors of sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial injury and apoptotic cell killing |
| Q33849293 | Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l |
| Q36399234 | Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy |
| Q28203099 | Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells |
| Q39905584 | Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. |
| Q36263997 | Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy |
| Q33803816 | Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells |
| Q34425447 | Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling |
| Q73140673 | Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation |
| Q35756901 | Interferon-gamma and TRAIL in human breast tumor cells |
| Q43613076 | Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways |
| Q33471546 | Intravital imaging of tumor apoptosis with FRET probes during tumor therapy |
| Q60489570 | Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells |
| Q34320209 | Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis |
| Q80761758 | Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway |
| Q24798681 | Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis |
| Q38557486 | Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. |
| Q40069326 | Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis |
| Q40598593 | Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway |
| Q43873071 | Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway |
| Q34607094 | MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells |
| Q35784718 | MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells |
| Q52647643 | Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells. |
| Q42099676 | Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. |
| Q39770080 | Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents |
| Q33805582 | Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. |
| Q35756898 | Modulation of TRAIL signaling for cancer therapy |
| Q43777335 | Molecular cross-talk between the TRAIL and interferon signaling pathways. |
| Q47830565 | Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression. |
| Q35058563 | Molecular imaging in drug discovery and development |
| Q34448123 | Molecular imaging: an overview |
| Q47628054 | Molecular requirements for the combined effects of TRAIL and ionising radiation |
| Q35224703 | Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy |
| Q44757357 | N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines |
| Q34429029 | Noninvasive real-time imaging of apoptosis |
| Q34490963 | Noninvasive strategies to image cardiovascular apoptosis |
| Q92344226 | Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox |
| Q37586895 | Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer |
| Q39129326 | Oncolytic viruses: emerging options for the treatment of breast cancer |
| Q40560857 | Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms |
| Q40486967 | Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. |
| Q34052992 | Predicting and monitoring cancer treatment response with diffusion-weighted MRI. |
| Q35940509 | Predicting treatment efficacy via quantitative magnetic resonance imaging: a Bayesian joint model |
| Q33991741 | Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis |
| Q40643048 | Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. |
| Q30930689 | Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI |
| Q39691093 | Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway |
| Q36769980 | Promise and progress for functional and molecular imaging of response to targeted therapies. |
| Q36292878 | Promoting apoptosis as a strategy for cancer drug discovery |
| Q35091424 | Protein-based therapeutic approaches targeting death receptors |
| Q41135950 | Quantifying initial cellular events of mouse radiation lymphomagenesis and its tumor prevention in vivo by positron emission tomography and magnetic resonance imaging |
| Q36489164 | RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling |
| Q30473856 | Radiation-induced tumor neoantigens: imaging and therapeutic implications. |
| Q40125508 | Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors |
| Q35218738 | Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival |
| Q60954603 | Radiotherapy as a New Player in Immuno-Oncology |
| Q34313135 | Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer |
| Q92306380 | Rational combinations of immunotherapy with radiotherapy in ovarian cancer |
| Q38871797 | Rays Sting: The Acute Cellular Effects of Ionizing Radiation Exposure |
| Q44611172 | Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo |
| Q36491838 | Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain |
| Q89885932 | Reflectance structured illumination imaging of internalized cerium oxide nanoparticles modulating dose-dependent reactive oxygen species in breast cancer cells |
| Q36731304 | Regulation of ERα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: Implications for breast cancer cell survival |
| Q39461469 | Regulation of cell death in cancer-possible implications for immunotherapy |
| Q35756915 | Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. |
| Q35038784 | Regulators of apoptosis as anticancer targets |
| Q39256130 | Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation |
| Q33288897 | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
| Q39985088 | Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism |
| Q43579921 | Sensitization of human colon cancer cells to TRAIL-mediated apoptosis |
| Q42713862 | Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. |
| Q73787189 | Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells |
| Q36149126 | Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. |
| Q33414714 | Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model |
| Q38007167 | TNF related apoptosis-inducing ligand and its receptors in ocular tumors |
| Q38491305 | TNF superfamily gene polymorphism as prognostic factor in early breast cancer |
| Q37440765 | TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies |
| Q36365504 | TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer |
| Q36781882 | TPL2 kinase is a suppressor of lung carcinogenesis |
| Q35927476 | TRAIL and its receptors as targets for cancer therapy |
| Q43963746 | TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells |
| Q37307340 | TRAIL gene therapy: from preclinical development to clinical application |
| Q34291312 | TRAIL in cancer therapy: present and future challenges |
| Q37040429 | TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype |
| Q36572530 | TRAIL receptor-targeted therapy. |
| Q99408898 | TRAIL signals, extracellular matrix and vessel remodelling |
| Q35239558 | TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression |
| Q39197722 | TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells |
| Q36895805 | TRAIL-receptor antibodies as a potential cancer treatment |
| Q34482821 | TRAIL/Apo-2L: mechanisms and clinical applications in cancer |
| Q38676416 | Targeting Melanoma with Cancer-Killing Viruses |
| Q42175008 | Targeting apoptosis signaling pathways for anticancer therapy |
| Q34791120 | Targeting death and decoy receptors of the tumour-necrosis factor superfamily |
| Q36832154 | Targeting death-inducing receptors in cancer therapy |
| Q36511919 | The TRAIL to targeted therapy of breast cancer |
| Q38185905 | The anti-tumor activity of E1A and its implications in cancer therapy |
| Q28478349 | The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL |
| Q36533669 | The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers |
| Q40311281 | The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells |
| Q28194460 | The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell |
| Q35755404 | The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester |
| Q40295172 | The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors |
| Q39730680 | The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma |
| Q34837015 | The emergence of resistance to targeted cancer therapeutics |
| Q31043513 | The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome |
| Q37187098 | The role of clinical imaging in oncological drug development |
| Q30973716 | The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies |
| Q35209364 | Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools |
| Q45865848 | Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus |
| Q73580654 | Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma |
| Q36865726 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. |
| Q40615752 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. |
| Q43687803 | Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines |
| Q27021391 | Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer |
| Q43903493 | Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. |
| Q34595455 | Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma |
| Q40789234 | Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. |
| Q92408464 | Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics |
| Q40609519 | Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers |
| Q34096601 | Use of new imaging techniques to predict tumour response to therapy |
| Q35683131 | WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. |
| Q73467719 | [Clinical applications of TRAIL in cancers. The prostate cancer example] |
Search more.